{"id":"b-cbdca-and-radiotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Radiation-related toxicity (mucositis, dermatitis)"}]},"_chembl":{"chemblId":"CHEMBL48208","moleculeType":"Small molecule","molecularWeight":"610.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin is a second-generation platinum compound that binds to DNA and forms interstrand crosslinks, preventing DNA replication and transcription in cancer cells. When combined with radiotherapy, it acts as a radiosensitizer, enhancing the cytotoxic effects of radiation therapy. This combination approach is designed to improve local tumor control and overall treatment efficacy in solid tumors.","oneSentence":"CBDCA (carboplatin) is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, used in combination with radiotherapy to enhance tumor control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:21.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors treated with concurrent chemoradiotherapy (specific tumor type dependent on trial protocol)"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT03604991","phase":"PHASE2, PHASE3","title":"Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-03","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8","enrollment":278},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT03044613","phase":"PHASE1","title":"Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-07-11","conditions":"Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer","enrollment":32},{"nctId":"NCT07394387","phase":"PHASE2","title":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-01","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":39},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06667908","phase":"PHASE2","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2024-12-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT06333899","phase":"EARLY_PHASE1","title":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-08-03","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":15},{"nctId":"NCT06193759","phase":"PHASE1","title":"Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-09-20","conditions":"Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes","enrollment":12},{"nctId":"NCT02402920","phase":"PHASE1","title":"Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-22","conditions":"Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm","enrollment":83},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT06401330","phase":"PHASE3","title":"A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-04-15","conditions":"Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor","enrollment":1656},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT04322318","phase":"PHASE2","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-10-19","conditions":"Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor","enrollment":256},{"nctId":"NCT04892953","phase":"PHASE2","title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8","enrollment":51},{"nctId":"NCT06656598","phase":"PHASE2","title":"Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-11-07","conditions":"Stage III NSCLC","enrollment":152},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT07022483","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-09-30","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT03323463","phase":"PHASE2","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-10-16","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck","enrollment":316},{"nctId":"NCT05978193","phase":"PHASE2","title":"Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT03937843","phase":"PHASE2","title":"Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2019-07-29","conditions":"Seminoma, Testicular Cancer","enrollment":135},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT02213497","phase":"PHASE1","title":"Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2014-04","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT02176967","phase":"PHASE3","title":"Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2014-08-08","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":621},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT02866136","phase":"PHASE2","title":"Conservative Treatments of Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2012-02","conditions":"Retinoblastoma, Children, Retinal Neoplasm","enrollment":133},{"nctId":"NCT05307939","phase":"PHASE2","title":"A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-03-24","conditions":"HPV, Oropharynx Cancer, HPV-Related Carcinoma","enrollment":30},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT01096368","phase":"PHASE3","title":"Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-05-07","conditions":"Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma","enrollment":479},{"nctId":"NCT06623656","phase":"PHASE2","title":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-02-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":112},{"nctId":"NCT04443348","phase":"PHASE2","title":"Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura M. Spring, MD","startDate":"2020-12-16","conditions":"Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)","enrollment":120},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT07153952","phase":"PHASE1, PHASE2","title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-01","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy","enrollment":60},{"nctId":"NCT00186888","phase":"PHASE3","title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04-07","conditions":"Retinoblastoma, Retinal Neoplasm","enrollment":107},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT07035808","phase":"PHASE2","title":"a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-01","conditions":"Cervical Cancer Stage IVA, Cervical Cancer Metastatic","enrollment":46},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT06905145","phase":"","title":"Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-05-03","conditions":"Head and Neck Squamous Cell Carcinoma, Locally Advanced Stage","enrollment":128},{"nctId":"NCT05179447","phase":"NA","title":"PROfiling Based Endometrial Cancer Adjuvant Therapy","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2022-01-24","conditions":"Endometrial Cancer Stage I, Endometrial Cancer Stage II","enrollment":590},{"nctId":"NCT03631784","phase":"PHASE2","title":"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-19","conditions":"Non-small Cell Lung Cancer","enrollment":216},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT01898494","phase":"PHASE2","title":"Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-01-22","conditions":"Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx","enrollment":519},{"nctId":"NCT01593241","phase":"PHASE2","title":"Therapy De-escalation in Seminoma Stage IIA/B","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2012-06-15","conditions":"Seminoma","enrollment":120},{"nctId":"NCT00554788","phase":"PHASE3","title":"Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-05-06","conditions":"Extraocular Retinoblastoma","enrollment":60},{"nctId":"NCT06752135","phase":"","title":"Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience","status":"TERMINATED","sponsor":"Azienda Policlinico Umberto I","startDate":"2024-04-10","conditions":"Cervical Carcinoma","enrollment":97},{"nctId":"NCT05655260","phase":"NA","title":"PErsonalized TReatment for Endometrial Carcinoma","status":"RECRUITING","sponsor":"University of Helsinki","startDate":"2022-02-08","conditions":"Endometrial Adenocarcinoma","enrollment":300},{"nctId":"NCT04952597","phase":"PHASE2","title":"Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-07-15","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT01899989","phase":"PHASE1","title":"Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-07-05","conditions":"Non-small Cell Lung Cancer","enrollment":39},{"nctId":"NCT02258659","phase":"PHASE2","title":"Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-09-22","conditions":"Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx","enrollment":62},{"nctId":"NCT06084845","phase":"PHASE2","title":"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-04-12","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT06490029","phase":"","title":"Diagnostic of Various Ototoxicity Induced by Cancer Treatment","status":"RECRUITING","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2024-06-19","conditions":"Ototoxicity, Drug-Induced","enrollment":540},{"nctId":"NCT04435197","phase":"PHASE2","title":"Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-08-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":143},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT06323369","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":154},{"nctId":"NCT05582265","phase":"PHASE3","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-10-28","conditions":"Head and Neck Squamous Cell Carcinomas","enrollment":537},{"nctId":"NCT02265770","phase":"PHASE2, PHASE3","title":"An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2015-06-02","conditions":"Childhood Ependymoma","enrollment":536},{"nctId":"NCT00653068","phase":"PHASE3","title":"Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-10","conditions":"Childhood Atypical Teratoid/Rhabdoid Tumor","enrollment":70},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT05529251","phase":"PHASE2","title":"De-escalation Study for Stage IIa/IIb < 3 cm Seminoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-09-06","conditions":"Seminoma, Stage II","enrollment":90},{"nctId":"NCT04992780","phase":"PHASE2","title":"Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-25","conditions":"Non Small Cell Lung Cancer Stage","enrollment":50},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT04572100","phase":"PHASE1","title":"Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-10-01","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT02578641","phase":"PHASE3","title":"A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients","status":"COMPLETED","sponsor":"Tessa Therapeutics","startDate":"2014-07","conditions":"Nasopharyngeal Carcinoma","enrollment":330},{"nctId":"NCT00632853","phase":"PHASE3","title":"Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2008-03","conditions":"Lung Cancer","enrollment":731},{"nctId":"NCT05872724","phase":"PHASE2","title":"Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","status":"RECRUITING","sponsor":"Suzhou Municipal Hospital","startDate":"2023-01-16","conditions":"Cervical Cancer","enrollment":32},{"nctId":"NCT03544736","phase":"PHASE1, PHASE2","title":"Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-04-26","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT00079417","phase":"PHASE3","title":"Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-12-26","conditions":"Intraocular Retinoblastoma","enrollment":28},{"nctId":"NCT05429463","phase":"PHASE3","title":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-11-11","conditions":"Squamous Cell Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT05650216","phase":"PHASE2","title":"Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2022-12-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT05524389","phase":"PHASE3","title":"Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-12-01","conditions":"Endometrial Cancer, Adjuvant Radiotherapy, Molecular Classification","enrollment":624},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT00712582","phase":"PHASE2","title":"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT00887783","phase":"PHASE2","title":"Navelbine And Radiotherapy in Locally Advanced Lung Cancer","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2009-05-01","conditions":"Non-small Cell Lung Cancer","enrollment":117},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT02934503","phase":"PHASE2","title":"Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2017-01-23","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":5},{"nctId":"NCT00402883","phase":"PHASE2","title":"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-11","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT03872505","phase":"PHASE2","title":"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT00003816","phase":"PHASE2, PHASE3","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1998-10-19","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":361},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT03151642","phase":"","title":"A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-04-05","conditions":"Esophageal Cancer","enrollment":11},{"nctId":"NCT04691063","phase":"PHASE3","title":"The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-01-22","conditions":"Small-cell Lung Cancer","enrollment":486},{"nctId":"NCT00285415","phase":"PHASE2","title":"A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation","status":"TERMINATED","sponsor":"Carilion Clinic","startDate":"2005-04","conditions":"Advanced Endometrial Adenocarcinoma, Stage III A, B, C","enrollment":46},{"nctId":"NCT03945227","phase":"PHASE2","title":"Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2019-06","conditions":"Stage III NSCLC","enrollment":""},{"nctId":"NCT00278148","phase":"PHASE1, PHASE2","title":"Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Nathan Pennell, MD, PhD","startDate":"2005-10","conditions":"Lung Cancer","enrollment":32},{"nctId":"NCT02792036","phase":"PHASE1","title":"Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-01","conditions":"Retinoblastoma","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"B: CBDCA and Radiotherapy","genericName":"B: CBDCA and Radiotherapy","companyName":"Japan Clinical Oncology Group","companyId":"japan-clinical-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CBDCA (carboplatin) is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, used in combination with radiotherapy to enhance tumor control. Used for Solid tumors treated with concurrent chemoradiotherapy (specific tumor type dependent on trial protocol).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}